Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) - Equities research analysts at Zacks Research reduced their Q1 2024 EPS estimates for shares of Integra LifeSciences in a research note issued to investors on Wednesday, April 3rd. Zacks Research analyst R. Department now expects that the life sciences company will post earnings of $0.55 per share for the quarter, down from their previous estimate of $0.57. The consensus estimate for Integra LifeSciences' current full-year earnings is $3.19 per share. Zacks Research also issued estimates for Integra LifeSciences' Q4 2024 earnings at $1.00 EPS, Q4 2025 earnings at $1.03 EPS, Q1 2026 earnings at $0.72 EPS and FY2026 earnings at $3.89 EPS.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. During the same quarter last year, the firm posted $0.94 earnings per share. Integra LifeSciences's revenue was down .3% on a year-over-year basis.
IART has been the topic of a number of other reports. Citigroup upgraded shares of Integra LifeSciences from a "sell" rating to a "neutral" rating and set a $38.00 price target on the stock in a research report on Wednesday. JMP Securities reduced their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a "market outperform" rating on the stock in a research report on Thursday, February 29th. StockNews.com lowered shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a research report on Friday. Finally, Truist Financial reduced their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a "hold" rating on the stock in a research report on Friday, March 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Integra LifeSciences presently has a consensus rating of "Hold" and an average target price of $44.89.
Check Out Our Latest Stock Report on IART
Integra LifeSciences Price Performance
Shares of Integra LifeSciences stock traded up $0.20 during trading on Friday, hitting $34.00. 674,584 shares of the company's stock traded hands, compared to its average volume of 652,862. The company has a market cap of $2.67 billion, a PE ratio of 40.96, a PEG ratio of 1.02 and a beta of 1.12. Integra LifeSciences has a twelve month low of $33.24 and a twelve month high of $59.33. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The firm's fifty day moving average price is $38.54 and its 200 day moving average price is $39.49.
Hedge Funds Weigh In On Integra LifeSciences
Institutional investors have recently modified their holdings of the stock. Signaturefd LLC raised its stake in shares of Integra LifeSciences by 248.5% in the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company's stock worth $25,000 after acquiring an additional 415 shares during the last quarter. Hexagon Capital Partners LLC raised its stake in shares of Integra LifeSciences by 123.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company's stock worth $29,000 after buying an additional 370 shares during the last quarter. Itau Unibanco Holding S.A. raised its stake in shares of Integra LifeSciences by 469.5% during the second quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company's stock worth $31,000 after buying an additional 615 shares during the last quarter. Gladius Capital Management LP bought a new stake in shares of Integra LifeSciences during the third quarter worth approximately $48,000. Finally, Covestor Ltd raised its stake in shares of Integra LifeSciences by 63.0% during the first quarter. Covestor Ltd now owns 1,558 shares of the life sciences company's stock worth $100,000 after buying an additional 602 shares during the last quarter. 84.78% of the stock is owned by institutional investors.
Integra LifeSciences Company Profile
(
Get Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Read More
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
